Compare Mesoblast Limited (MESO) vs ArcelorMittal SA (MT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs ArcelorMittal SA — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.81B), while ArcelorMittal SA trades at $64.02 (market cap $47.06B). The key difference: ArcelorMittal SA is far larger — about 26× Mesoblast Limited's market cap, and ArcelorMittal SA pays a 0.96% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and ArcelorMittal SA for 36 Days on average.
| MESO | MT | |
|---|---|---|
Market Cap | $1.81B | $47.06B |
Volume | 240,620 | 1,545,197 |
Sector | Health | Basic Materials |
52-Week High | $20.96 | $78.74 |
52-Week Low | $13.19 | $36.91 |
Typical Hold Time | 14 Days | 36 Days |
Enterprise Value | $1.89B | $56.63B |
Dividend Yield | — | 0.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
ArcelorMittal (MT) trades at $62.32, down 4.4% today, with technical indicators signaling bearish momentum. The stock shows mixed fundamentals with revenue declining from $79.8B in 2022 to $61.4B in 2025, though net income improved to $3.2B. Recent news highlights operational disruptions at its Ukrainian plant with a potential $1B impairment charge, while analyst consensus remains positive with a $74.33 price target.
The outlook is cautious due to geopolitical risks and declining revenue trends, but valuation metrics appear reasonable with P/E of 26.2 and P/B of 0.86. Investment opportunity exists if European operations stabilize and growth projects deliver, though investors face headwinds from steel demand volatility and ongoing Ukraine-related impairments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →
